Circulating Tumour Cell Enrichment Technologies

Circulating Tumour Cell Enrichment Technologies: History

Please note this is an old version of this entry, which may differ significantly from the current revision.

Subjects: Oncology

Contributor: Amelia Rushton

Circulating tumour cells (CTCs) are the precursor cells for the formation of metastatic disease. With a simple blood draw, liquid biopsies enable the non-invasive sampling of CTCs from the blood, which have the potential to provide important insights into cancer detection and monitoring. Since gaining FDA approval in 2004, the CellSearch system has been used to determine the prognosis of patients with metastatic breast, prostate and colorectal cancers. This utilises the cell surface marker Epithelial Cell Adhesion Molecule (EpCAM), to enrich CTCs, and many other technologies have adopted this approach. More recently, the role of mesenchymal-like CTCs in metastasis formation has come to light. It has been suggested that these cells are more aggressive metastatic precursors than their epithelial counterparts; however, mesenchymal CTCs remain undetected by EpCAM-based enrichment methods. This has prompted the development of a variety of ‘label free’ enrichment technologies, which exploit the unique physical properties of CTCs (such as size and deformability) compared to other blood components.

circulating tumour cell (CTC)
cancer
metastasis
liquid biopsy

Note: The following contents are extract from your paper. The entry will be online only after author check and submit it.

1. Introduction

Circulating tumour cells (CTCs) are shed into the bloodstream from both primary and metastatic tumours and those that are able to survive in the circulation represent metastatic precursor cells [1]. CTCs are important biomarkers for disease and are a powerful tool to study tumour progression and evolution. They represent a rare and heterogeneous population of cells, typically accounting for ∼1 cells for every 10⁵–10⁶ peripheral blood mononuclear cells (PBMCs), so a key challenge for their clinical utility is the development of standardised isolation and characterisation technologies [2]. There are numerous technologies that have been developed to enrich CTCs from normal hematopoietic cells that rely on physical and biological properties of CTCs, including size, density, cellular charge and expression of cellular markers. The enrichment techniques (Table 1) can broadly be divided into immunocapture methods that differentiate cells based on epithelial cell surface marker expression, notably epithelial cell adhesion molecule (EpCAM) (Figure 1A), and those that differentiate based on distinct biophysical properties (Figure 1B,C). If CTC enrichment and characterisation is to be routinely used in the clinical setting, technologies must ideally meet several criteria: they must have high detection and recovery rates, with accurate throughput sample processing and enumeration capability. Further, they must be generally fully automated and easy to use, with little to no pre-processing of blood required. Finally, if they are to have wide clinical applicability, they must be able to detect heterogeneous cells from a wide range of different cancers.

Figure 1. Summary of circulating tumour cell (CTC) enrichment technologies. (A) Immunocapture methods including immunomagnetic positive and negative enrichment methods, microfluidic immunocapture methods, nanomaterial immunocapture enhancement and their relevant technologies; (B) Biophysical property enrichment methods including membrane filtration, size-based microfluidics, density based and dielectrophoresis and associated technologies; (C) Other methods including in vitro, combined and secondary isolation methods and associated technologies.

Table 1. CTC isolation technologies, grouped based on enrichment method. Capture efficiency, recovery rate and advantages and disadvantages of the technologies are also shown.

Subcategory	Name	Capture Efficiency (%)	Recovery Rate (%)	Advantages	Disadvantages
Subcategory	Name	Capture Efficiency (%)	Recovery Rate (%)	Advantages	Disadvantages
Immunomagnetic enrichment
Immunomagnetic positive enrichment	CellSearch [3–7]	42–90		Semi automated Can process up to 8 samples at a time In device staining CTC enumeration via CellTracks Analyser FDA approved	Recovery of EpCAM⁺ CTCs only Only able to detect CTCs expressing high levels of EpCAM
	MACS [8,9]	25–90		Cocktail of antibodies available to increase CTC capture Able to process up to 15 mL blood Easy elution of CTCs Pro Separator can process up to 6 samples at once	Recovery of EpCAM⁺ CTCs only Suggested the MACS system is better suited for tissue samples
	MagSweeper [10,11]	60–70		Nonadherent plastic sleeves allow for multiple rounds of capture to increase capture efficiency	Recovery of EpCAM⁺ CTCs only
	Strep-tag [12,13]	79–86	70	Easy release of CTCs by simple addition of d-biotin Possibility to use a cocktail of antibodies to increase capture	Recovery of EpCAM⁺ CTCs only
	IMS [14]	92		Leukocytes repelled so high purity recoveries	Recovery of EpCAM⁺ CTCs only Not yet tested on patient samples
Immunomagnetic negative enrichment	EasySep [15,16]	19–65		Recovery of heterogeneous population of CTCs	Exclusion of CTC-WBC clusters Variable recovery rates May inadvertantly remove CTCs
	RosetteSep [17]	62.5		Recovery of heterogeneous population of CTCs Cocktail of antibodies used to maximise depletion	Exclusion of CTC-WBC clusters, May inadvertantly remove CTCs
Microfluidic immunocapture positive enrichment	CTC-Chip [18,19]		>60	Large surface area for CTC capture High viability of recovered cells	Recovery of EpCAM⁺ CTCs only Slow processing rate Complex geometry of chip difficult to scale up Geometry prevents passage of CTC clusters
	HB-chip [20]	74.5–97		HB grooves increase CTC-antibody contact for increased cell capture	Recovery of EpCAM⁺ CTCs only
	GEDI chip [21]	80–90		Large surface area for CTC capture Possibility to functionalise with alternative antibodies	May miss heterogeneity of CTCs
	HTMSU [22]	>97		Quick processing On-chip single-cell conductometric counting for enumeration	Recovery of EpCAM⁺ CTCs only
	Nanovelcro [23]	70–95		4 generations developed for different clinical utilities 3rd and 4th generation chips adapted for easy CTC release	Recovery of EpCAM⁺ CTCs only
	Isoflux [4]	74–90	64–75	Utilises microfluidic approach to increase EpCAM sensitivity Up to 4 samples can be processed in parallel Multiple kits including cocktails of antibodies to capture heterogeneity IsoFlux Cytation Imager for sample scanning
Capture enhancement by nanomaterials	NP-^HBCTC-Chip [24]	79–97		Simple release of CTCs by addition of glutathione (GSH) Chip surface can be functionalised with a cocktail of antibodies for enhanced capture efficiency	Recovery of EpCAM⁺ CTCs only Very low throughput
	GO chip [25,26]	67–100	91–95	Simple chip design Large surface area for increased CTC capture	Recovery of EpCAM⁺ CTCs only
	SiNP [27]	84–91		Large surface area for CTC capture	Recovery of EpCAM⁺ CTCs only
Capture enhancement by nanomaterials	Nanotube-CTC-chip [28]	89–100		Preferential adherence negates need for EpCAM antibodies Planar enrichment surface makes chip visualisation and imaging easy	Time taken for optimal CTC adherence to substrate is too long
Size based enrichment
Membrane filtration	FMSA [29]	90		Recovery of heterogeneous population of CTCs Cheap and easy to produce Quick processing time	Filter clogging highly likely
	ScreenCell [30]		74–91	Recovery of heterogeneous population of CTCs Cheap and easy to produce Three different devices offered depending on downstream requirements Quick processing time	Unevenly distributed or fused pores can reduce capture efficiency
	ISET [31,32]		83–100	Recovery of heterogeneous population of CTCs Cheap and easy to produce Ability to process 12 samples in parallel	Slow processing time Blood must be diluted 1:10 to prevent membrane clogging
	SB microfilter [33]	78–83		Recovery of heterogeneous population of CTCs Cheap and easy to produce Quick processing time	Only 1 mL blood can be processed at a time due to device clogging
	FAST [34]		94–98	Recovery of heterogeneous population of CTCs Cheap and easy to produce Quick processing time
Microfluidics	Parsortix [35]	42–70	54–69	Recovery of heterogeneous population of CTCs Ability to capture CTC clusters Option for on-chip staining	Slow processing time On-chip imaging difficult
	MCA [36]	>90	68–100	Recovery of heterogeneous population of CTCs Option for on-chip staining Ability to process up to 4 samples in parallel
	ClearCell FX1 [37,38]		52–79	Recovery of heterogeneous population of CTCs Quick processing time No channel clogging observed
	Vortex VTX-1 [39,40]		53.8–71.6	Recovery of heterogeneous population of CTCs Filters at channel inlet prevent channel clogging Fully automated process Quick processing time Associated BioView for enumeration Option to run in “high recovery” or “high purity” mode
	p-MOFF [41]		91.6–93.75	Recovery of heterogeneous population of CTCs Quick processing time No channel clogging observed	RBC lysis and Ficoll density centrifugation required
Density based	OncoQuick [42,43]	25–87		Recovery of heterogeneous population of CTCs Up to 25 mL blood can be processed per tube	Low detection and recoveryrates
	AccuCyte [44]		81–90.5	Recovery of heterogeneous population of CTCs Allows for processing of multiple samples in parallel Associated CyteFinder and CytePicker systems for imaging and mechanical selection of CTCs
Other
Dielectrophoresis	ApoStream [45,46]		55–78.5	Recovery of heterogeneous population of CTCs Quick processing time iCys laser scanning cytometer for enumeration High viability of recovered cells
In vivo	Diagnostic leukapheresis (DLA) [47]			Recovery of heterogeneous population of CTCs Recovery of much greater numbers of CTCs	Only a pre-enrichment step so must be used in combination with another enrichment technology Huge leukocyte background
	GILUPI CellCollector [48]			Potential for much greater numbers recovered	More invasive for the patient than a simple blood draw Recovery of EpCAM⁺ CTCs only
Combined	CTC-iChip [49]		70–100	Option for positive or negative enrichment approach Inertial focusing provides high sensitivity selection Quick processing time	Positive enrichment only allows for recovery of EpCAM⁺ CTCs Negative enrichment will exclude CTC-WBC clusters
	^LPCTC-iChip [50]		85.5–100	Potential for much greater numbers recovered Magnetic field directs WBCs to centre of channel to prevent channel clogging Extremely high throughput	Disregards CTC-WBC clusters Initial debulking step may result in CTC loss
	OPENchip [51]		50	Chip allows for CTC enrichment and on-chip downstream molecular analysis	Low throughput, low recovery rates

This entry is adapted from the peer-reviewed paper 10.3390/cancers13050970

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.